iDose TR: A Revolutionary Sustained-Release Treatment for Glaucoma and Ocular Hypertension

iDose TR: A Revolutionary Sustained-Release Treatment for Glaucoma and Ocular Hypertension

I am not sponsored by the company in any way. My patients with Ocular Hypertension (OHTN) and or Glaucoma (nerve damage) continue to develop significant Dry Eye disease from the preservatives in their glaucoma drops. If there is any way to get these patients off their preservative-filled eye drops (knowing most insurance is still do not cover preservative free versions of these drops), I will recommend this. Getting patients off their preservative filled eye dropswill help save sensitive cells which can lead to chronic dryness and pain. 

Managing glaucoma and ocular hypertension has traditionally required daily eye drops, which many patients struggle to use consistently. iDose TR (travoprost intracameral implant) represents a breakthrough in glaucoma care—a tiny implant that delivers continuous medication for up to three years after a single administration.  

  

What is iDose TR?

  

  

iDose TR is an FDA-approved intracameral implant containing travoprost, a prostaglandin analog that lowers intraocular pressure (IOP) by increasing uveoscleral outflow. The implant is placed in the eye during a brief in-office procedure and continuously releases medication, eliminating the need for daily eye drops in most patients.  

  

Who is iDose TR For?

  

  

iDose TR is indicated for patients with open-angle glaucoma or ocular hypertension who need IOP reduction. It's particularly beneficial for patients who:  

  

- Struggle with adherence to daily eye drop regimens  

  

- Experience side effects from topical medications  

  

- Have difficulty administering eye drops due to physical limitations  

  

- Prefer a long-term solution that reduces treatment burden  

  

Clinical Trial Results

  

  

The efficacy of iDose TR has been demonstrated in multiple rigorous clinical trials:  

  

IOP Reduction: In two pivotal Phase 3 trials involving over 1,150 patients, iDose TR achieved IOP reductions of 6.6 to 8.4 mmHg from a baseline of 24 mmHg during the first three months. The implant demonstrated non-inferiority to twice-daily timolol eye drops.  

  

Medication-Free Success: At 12 months, 77.6% to 81.4% of patients with the implant were completely free of all topical IOP-lowering medications. Among patients who were on medications before treatment, 80-85% were able to reduce their medication burden.  

  

Long-Term Durability: Phase 2 data extending to 36 months showed sustained IOP reductions of 7.3 to 8.8 mmHg, with 63-69% of patients remaining well-controlled on the same or fewer medications compared to their pre-treatment regimen.  

  

Real-World Performance: Recent real-world data showed a 33.2% IOP reduction (from 19.6 to 13.1 mmHg) at 3 months, with 83.3% of eyes achieving IOP ≤15 mmHg and 100% remaining medication-free.  

  

Safety Profile

  

  

iDose TR has demonstrated a favorable safety profile in clinical trials involving 868 patients followed for one year:  

  

Common Side Effects (2-6% of patients):  

  

- Transient IOP increases  

  

- Iritis (inflammation)  

  

- Dry eye  

  

- Visual field defects  

  

- Eye pain  

  

- Ocular redness  

  

- Reduced visual acuity  

  

Less Common Side Effects (2% of patients):  

  

- Conjunctival hemorrhage  

  

- Light sensitivity  

  

- Punctate keratitis  

  

- Device dislocation  

  

- Corneal abrasion  

  

Most adverse events were mild to moderate in severity. Iritis, when it occurred, typically responded well to topical corticosteroids. The implant has minimal systemic absorption, with plasma travoprost levels below detectable limits.  

  

Important Contraindications

  

  

iDose TR should NOT be used in patients with:  

  

- Active or suspected ocular or periocular infections  

  

- Corneal endothelial dystrophy (e.g., Fuchs' Dystrophy, corneal guttata)  

  

- Prior corneal transplantation or endothelial cell transplants (e.g., DSAEK)  

  

- Hypersensitivity to travoprost or any component of the product  

  

Special Precautions

  

  

Corneal Endothelial Cell Density: Before implantation, patients must meet minimum corneal endothelial cell density requirements based on age and lens status. For pseudophakic patients over 65 years, the minimum is 1,120 cells/mm². Regular monitoring is essential, and readministration should be approached cautiously if there is ≥10% endothelial cell loss.  

  

Use with Caution in:  

  

- Patients with narrow iridocorneal angles (Shaffer grade 3)  

  

- Aphakic patients or pseudophakic patients with torn posterior lens capsule  

  

- Patients with risk factors for macular edema  

  

- Patients with active intraocular inflammation (e.g., uveitis)  

  

Pigmentation: Like other prostaglandin analogs, iDose TR may cause increased brown pigmentation of the iris, which is likely to be permanent. Patients should be informed of this possibility and monitored regularly.  

  

Device Monitoring: Patients should be monitored routinely to confirm the implant remains properly positioned. If dislocation occurs, surgical removal is required.  

  

Administration Guidelines

  

  

- iDose TR is administered as an intracameral implant under sterile conditions  

  

- Should not be readministered more than once per year  

  

- Proper aseptic technique is essential to prevent [endophthalmitis](/rare-disease/endophthalmitis)  

  

- Patients should be monitored following administration  

  

The Bottom Line

  

  

iDose TR represents a paradigm shift in glaucoma management, offering sustained IOP control for up to three years with a single administration. For appropriate candidates, it eliminates the daily burden of eye drops while maintaining excellent IOP control. The majority of patients remain completely medication-free at one year, with a favorable safety profile.  

  

If you're struggling with glaucoma eye drops or looking for a more convenient treatment option, ask your ophthalmologist whether iDose TR might be right for you.  

  

  

This information is based on comprehensive FDA labeling information and clinical trial data from multiple Phase 2 and Phase 3 studies.[1][2][3][4] The efficacy data comes from rigorous randomized controlled trials showing robust IOP reduction and significant medication burden reduction. The safety information reflects adverse event rates from 868 patients followed for one year in controlled clinical trials.[1] The contraindications and precautions are derived directly from FDA-approved prescribing information to ensure patient safety.[1]  

  

References

1. iDose TR. Food and Drug Administration. Updated date: 2026-02-04.

2. Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients With Open-Angle Glaucoma or Ocular Hypertension. Berdahl JP, Sarkisian SR, Ang RE, et al. Drugs. 2024;84(1):83-97. doi:10.1007/s40265-023-01973-7.

3. Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses From Two Phase III Trials. Singh IP, Berdahl JP, Sarkisian SR, et al. Drugs. 2024;84(10):1299-1311. doi:10.1007/s40265-024-02074-9.

4. Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension. Sarkisian SR, Ang RE, Lee AM, et al. Ophthalmology. 2024;131(9):1021-1032. doi:10.1016/j.ophtha.2024.02.022.